|
Testig method for nitroso Ciprofloxacin
|
|
3
|
105
|
October 3, 2023
|
|
Variation requirements
|
|
2
|
84
|
October 2, 2023
|
|
Visualization of Categorized Compounds by CPCA
|
|
45
|
2618
|
September 29, 2023
|
|
关于2023药物杂质控制国际交流会的资讯
|
|
1
|
88
|
September 29, 2023
|
|
Autonomous CPCA Web-based calculator FREE
|
|
16
|
443
|
September 27, 2023
|
|
N-nitroso Torasemide Impurity formation and control
|
|
14
|
389
|
September 26, 2023
|
|
🇺🇸 FDA - Recommended Acceptable Intake Limits for NDSRIs Guidance for Industry
|
|
47
|
2855
|
September 20, 2023
|
|
Nitrosamine in DS and DP specifications
|
|
2
|
285
|
September 20, 2023
|
|
Apixaban Drug Substance-Related Impurities (NDSRIs)
|
|
3
|
334
|
September 15, 2023
|
|
🇪🇺 EMA Q&A Rev. 16 EMA/409815/2020 - MAJOR UPDATE
|
|
108
|
6838
|
September 12, 2023
|
|
🖩 CPCA Calculation Tool (excel-based) -Updated
|
|
68
|
3236
|
September 11, 2023
|
|
Modeling the Impact of Excipients Selection on Nitrosamine Formation towards Risk Mitigation
|
|
1
|
333
|
September 8, 2023
|
|
DP Method transfer and verification
|
|
8
|
248
|
August 31, 2023
|
|
Optimized method development strategies for the quantification of small and complex N-nitrosamines impurities
|
|
0
|
194
|
August 25, 2023
|
|
Approaches and Considerations for the Investigation and Synthesis of N‑Nitrosamine Drug Substance-Related Impurities (NDSRIs)
|
|
0
|
210
|
August 23, 2023
|
|
Nitrosaminas: Estrutura química vs Potencial carcinogênico
|
|
3
|
245
|
August 23, 2023
|
|
N-Nitroso N-Desmethyl Nefopam
|
|
4
|
287
|
August 18, 2023
|
|
CPCA is now included in the updated version of Health Canada’s Guidance on nitrosamine impurities
|
|
12
|
669
|
August 16, 2023
|
|
Total impurities limit if more than one nitrosamine impurities are observed in product
|
|
4
|
259
|
August 14, 2023
|
|
Planilha CPCA na prática
|
|
0
|
150
|
August 6, 2023
|
|
Personal perspective on N-Nitrosamines and recent revision of guidelines
|
|
6
|
310
|
July 28, 2023
|
|
FDA Workshop: Mitigation Strategies for Nitrosamine Drug Substance Related Impurities
|
|
11
|
1446
|
July 27, 2023
|
|
Formation of N-Nitrosamine Drug Substance Related Impurities in Medicines: A Regulatory Perspective on Risk Factors and Mitigation Strategies
|
|
3
|
382
|
July 26, 2023
|
|
Case Studies for CPCA Scoring
|
|
12
|
1264
|
July 25, 2023
|
|
NDSRIs: Atualizações e Desafios
|
|
0
|
196
|
July 24, 2023
|
|
Pharmaceutical industry wants FDA to extend deadline for testing novel nitrosamines
|
|
3
|
468
|
July 21, 2023
|
|
Forced degradation: predicting nitrosamine formation
|
|
8
|
711
|
July 20, 2023
|
|
🇸🇦 Saudi FDA requesting Nitrosamines Risk Assessments
|
|
0
|
365
|
July 18, 2023
|
|
😞 Aripiprazole is not approvable since 'major objections' have been identified
|
|
6
|
387
|
July 18, 2023
|
|
Strategies for Mitigating In-Source Fragmentation in NDSRI Analysis using LC-MS
|
|
2
|
477
|
July 3, 2023
|